Skip to main content

Miragen Issued Notice of Allowance for microRNA-Related IP

Premium

Miragen Therapeutics this week announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering microRNAs that modulate smooth muscle proliferation and differentiation.

Specifically, the intellectual property claims methods of use in modulating miR-143, which the company said plays a critical role in controlling smooth muscle cells at the site of vascular injury.

Studies conducted by Miragen with collaborators at the University of Texas Southwestern Medical Center in a carotid artery ligation model demonstrated that “injection of synthetic mimics of miR-143 stopped blood vessel blockage by inhibiting stenosis at the site of vessel injury,” Miragen said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.